Table 2.
Group “Early” | Group “Late” | p Value | |
---|---|---|---|
Pre-treatment PSA* | 13.9 ng/mL (9.43) | 21.85 ng/mL (26.32) | 0.83 |
T stageΨ | 0.69 | ||
1c | 4/22 (18%) | 5/32 (16%) | |
2a-c | 11/22 (50%) | 20/32 (63%) | |
3a-b | 7/22 (32%) | 7/32 (22%) | |
Gleason score* | 6.6 (0.58) | 6.73 (1.04) | 0.76 |
median (range) | 3+4 (3+3 to 4+3) | 3+4 (2+3 to 5+4) | |
D'Amico's risk groupΨ | 0.33 | ||
high | 10/25 (40%) | 16/34 (47%) | |
intermediate | 10/25 (40%) | 16/34 (47%) | |
low | 5/25 (20%) | 2 (6%) | |
Radiation dose* | 75.5 Gy (3.27) | 74.3 Gy (3.73) | 0.31 |
Hormonal therapyΨ | 13/25 (52%) | 15/34 (44%) | 0.60 |
Biochemical failureΨ | 7/25 (28%) | 15/34 (44%) | 0.28 |
= mean (standard deviation)
= n (percentage).